Sudeep Pharma Limited (NSE:SUDEEPPHRM)
India · Delayed Price · Currency is INR 560.90
+19.30 (3.56%)
At close: Jan 23, 2026
Sudeep Pharma Revenue
Sudeep Pharma had revenue of 1.63B INR in the quarter ending September 30, 2025, with 42.12% growth. This brings the company's revenue in the last twelve months to 5.61B. In the fiscal year ending March 31, 2025, Sudeep Pharma had annual revenue of 5.02B with 9.30% growth.
Revenue (ttm)
5.61B
Revenue Growth
+9.30%
P/S Ratio
11.30
Revenue / Employee
11.68M
Employees
480
Market Cap
63.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.02B | 427.19M | 9.30% |
| Mar 31, 2024 | 4.59B | 305.42M | 7.12% |
| Mar 31, 2023 | 4.29B | 841.21M | 24.41% |
| Mar 31, 2022 | 3.45B | 3.38B | 4,999.06% |
| Mar 31, 2004 | 67.58M | -4.20M | -5.85% |
| Mar 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 21.70B |
| Neuland Laboratories | 15.33B |
| Shilpa Medicare | 13.43B |
| Bajaj HealthCare | 6.11B |
| NGL Fine-Chem | 4.08B |
| Infinium Pharmachem | 1.57B |
| Gujarat Themis Biosyn | 1.55B |
| Anlon Healthcare | 1.44B |